학술논문
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma
Document Type
Article
Author
Source
In: Leukemia and Lymphoma . (Leukemia and Lymphoma, 2023, 64(14):2225-2235)
Subject
Language
English
ISSN
10292403
10428194
10428194